NAPROSYN® PAIN RELIEF HEALTHCARE PROFESSIONAL TRAINING
A breakthrough in pharmacy pain management
Naprosyn® Pain Relief 250 mg tablets is a pharmacy-only treatment for adults aged 18 to 50 years of age, with conditions characterised by pain and inflammation of the muscles and joints, e.g. sprains and strains, sporting injuries, lower back pain, neck pain, or pain in the wrists or feet.1
Naprosyn® Pain Relief contains the non-steroidal anti-inflammatory drug (NSAID) naproxen 250 mg, which is long-established for the treatment of these conditions in the prescription field, but this is the first time it has been available in pharmacy specifically for the relief of musculoskeletal pain.
Opioid free, Naprosyn® Pain Relief offers powerful34 and long-lasting relief26, for the treatment of short-term muscle and joint pain and inflammation1.
Learning objectives
The overall aim of this training is to support you in providing effective, patient-centred, clinical consultations on common musculoskeletal pains and provide guidance on the appropriate supply of over-the-counter (OTC) Naprosyn® Pain Relief 250 mg gastro-resistant tablets (naproxen).
- To refresh your knowledge of the signs and symptoms of common musculoskeletal problems and over-the-counter analgesics
- To be aware of additional lifestyle counselling you can offer to those experiencing musculoskeletal pains
- To understand where Naprosyn® Pain Relief fits into the pharmacy pain portfolio in comparison to other OTC analgesics
- To know when to recommend Naprosyn® Pain Relief.
Order Naprosyn® Pain Relief for your pharmacy
Naprosyn® Pain Relief 250 mg gastro-resistant tablets (naproxen) will be available to order from major wholesalers including AAH, Alliance, Phoenix and Sigma from October 2025.
Alternatively, contact your Laser Team representative.
-
Naprosyn® Pain Relief 250 mg gastro-resistant tablets (Naproxen) PL 42807/0004. Indication: for the relief of short-term muscle and joint pain (such as sprains and strains, inflammation caused by sporting injuries, lower back pain, neck pain, or pain in the wrists or feet) in those aged 18-50 years. Posology: On the first day two tablets (500 mg) to be taken initially and then if needed, one tablet (250 mg) after 6-8 hours. On days 2 and 3, one tablet to be taken every 6-8 hours, if needed. Maximum daily dose of 3 tablets (750 mg), for a maximum of 3 days continuous use. Contraindications: hypersensitivity to naproxen, naproxen sodium or any of the excipients, patients with a history of, or active peptic ulcers and active gastrointestinal (GI) bleeding (two or more distinct episodes of proven ulceration or bleeding), history of GI bleeding or perforation related to previous NSAID therapy, aspirin or NSAID sensitivity, those taking any other NSAID or aspirin, patients with severe heart, hepatic or renal failure, women in the third trimester of pregnancy. Precautions: in the first 6 months of pregnancy, when breast-feeding or in women attempting to conceive. Caution in patients with bronchial asthma or allergic disease, cardiac impairment, hypertension, impaired renal function, liver dysfunction, peripheral arterial or cerebrovascular disease, history of GI disease (e.g., ulcerative colitis, Crohn’s disease), coagulation disorders, connective tissue disease, hyperlipidaemia, diabetes, smokers, and those taking oral corticosteroids, anticoagulants, antiplatelet agents, or SSRIs. Side effects: Hypersensitivity reactions including non-specific allergic reactions and anaphylaxis, respiratory tract reactivity e.g., asthma, bronchospasm, dyspnoea, various skin reactions e.g., pruritus, urticaria, purpura, angioedema, bullous reactions including epidermal necrolysis, erythema multiforme, Stevens-Johnson Syndrome, DRESS. GI ulceration or haemorrhage, peptic ulceration, or perforation, hyperkalaemia, cardiac and congestive heart failure, myocardial infarction, stroke, renal failure, jaundice, hepatitis, meningitis. MA Holder: Maxwellia Ltd, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, UK. Classification: P. RRP: 9 tablets £6.95. Date: August 2025.